Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, June 17, 2022, starting at 10:00 a.m. Pacific Time.
The live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2022. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting.
As described in the Company’s proxy statement, filed May 2, 2022, only shareholders of record as of the close of business on April 14, 2022, are entitled to vote at the Annual Meeting of Shareholders and any adjournment or postponement thereof. Shareholders of record will be able to attend the meeting, vote and submit questions via the Internet at www.virtualshareholdermeeting.com/OMER2022 using the 16-digit control number provided in their proxy card or in the instructions accompanying their proxy materials.
Guests without a 16-digit control number may also attend the Annual Meeting by accessing the website listed above, but will not have the option to vote or ask questions.
For those unable to attend the live event, a recording will be archived and accessible at https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is initiating a Phase 1b clinical program in paroxysmal nocturnal hemoglobinuria (PNH). In addition to its complement franchise, Omeros has ongoing cutting-edge programs in addiction treatments, immuno-oncology therapeutics and human CAR-T and adoptive T cell therapy systems. More information about Omeros and its programs is available at www.omeros.com and in Omeros’ annual, quarterly and current reports filed with the U.S. Securities and Exchange Commission (SEC), which can be accessed at www.omeros.com under “Investors & News — Financial Information — SEC Filings” and on the SEC’s website at www.sec.gov.
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations